EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EXO1 inhibition selectively kills replication repair-deficient cancer cells

Marija Maric, Sarah E McClelland, Simon J Boulton iD

NAR Cancer · 2026

DOI: 10.1093/narcan/zcag029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NAR Cancer, 2026. Verfasst von Marija Maric und 2 weiteren Autor:innen. Beteiligte Einrichtung: DSB Repair Metabolism Lab, The Francis Crick Institute, London NW1 1AT, United Kingdom. Hauptthemen laut MEDLINE: Exodeoxyribonucleases, DNA Replication, DNA Repair, DNA Repair Enzymes. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Francis Crick Institute, European Research Council Advanced Investigator.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Deficiencies in DNA repair pathways create context-specific vulnerabilities that may be exploited therapeutically. Recent studies have established EXO1 as a druggable nuclease, but the genetic contexts that confer sensitivity to EXO1 inhibition remain incompletely defined. Here, we assessed whether pharmacological inhibition of EXO1 selectively targets repair-deficient cancer cells across multiple DNA repair backgrounds. Using potent and selective EXO1 inhibitors, we demonstrate impaired viability in cells deficient for Fanconi Anaemia pathway components (FANCG and APITD1/MHF1), BRCA1-A complex factor BRCC36, and the spliceosome factor ZRSR2. EXO1 inhibition in FANCG or ZRSR2 KO cells induced accumulation of micronuclei, γH2AX, and RPA32 phosphorylation at serine 33, consistent with enhanced replication stress leading to cell death, and supporting a role for EXO1 in processing replication-associated DNA structures and maintaining genome stability under conditions of replication stress. Combining EXO1 inhibitor with PARP inhibitors exacerbated cytotoxicity, suggesting partially nonoverlapping repair functions and therapeutic potential for EXO1/PARP inhibitor combination strategies. Collectively, these findings establish that pharmacological inhibition of EXO1 recapitulates the sensitivity to genetic EXO1 loss in certain DNA repair deficient backgrounds, supporting its development as a targeted therapeutic strategy in molecularly stratified cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExodeoxyribonucleasesDNA ReplicationDNA RepairDNA Repair EnzymesEnzyme InhibitorsHumansPoly(ADP-ribose) Polymerase InhibitorsCell Line, TumorCell SurvivalPhosphorylationHistones

Substanzen

ExodeoxyribonucleasesEXO1 protein, humanDNA Repair EnzymesPoly(ADP-ribose) Polymerase InhibitorsEnzyme InhibitorsHistones

Autor:innen und Institutionen

  • DSB Repair Metabolism Lab, The Francis Crick Institute, London NW1 1AT, United Kingdom.
  • The Chromosomal Instability Lab, Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, United Kingdom.

ORCID-Profile: Simon J Boulton

Förderung

  • Wellcome Trust
  • Francis Crick Institute
  • European Research Council Advanced Investigator
  • Cancer Research UK RadNet City of London
  • Cancer Research UK Discovery Programme Foundation Award

Zitieren

APA

Maric, M., McClelland, S. E., & Boulton, S. J. (2026). EXO1 inhibition selectively kills replication repair-deficient cancer cells. NAR Cancer. https://doi.org/10.1093/narcan/zcag029

Vancouver

Maric M, McClelland SE, Boulton SJ. EXO1 inhibition selectively kills replication repair-deficient cancer cells. NAR Cancer. 2026. doi:10.1093/narcan/zcag029

BibTeX
@article{Maric2026,
  author = {Maric, Marija and McClelland, Sarah E and Boulton, Simon J},
  title = {EXO1 inhibition selectively kills replication repair-deficient cancer cells},
  journal = {NAR Cancer},
  year = {2026},
  doi = {10.1093/narcan/zcag029}
}
Kostenlos starten →